Curetis N.V. (the "Company" and, together with Curetis GmbH, "Curetis"), a developer of next-level molecular diagnostic solutions, today announced the recent presentation of new data demonstrating the clinical and health economic benefits of using the Company’s Unyvero ITI (Implant and Tissue Infections) Application for the diagnosis of prosthetic joint infections. Data were presented during this year’s European Congress of Clinical Microbiology and Infectious Diseases (ECCMID, April 22-25, 2017, Vienna/Austria).